Regner-Nelke, Liesa
Pawlitzki, Marc
Willison, Alice
Rolfes, Leoni
Oezalp, Sinem-Hilal
Nelke, Christopher
Kölsche, Tristan
Korsen, Melanie
Grothe, Matthias
Groppa, Sergiu
Luessi, Felix
Engel, Sinah
Nelles, Gereon
Bonmann, Eckhard
Roick, Holger
Friedrich, Anke
Knorn, Philipp
Landefeld, Harald
Biro, Zoltan
Ernst, Michael
Bayas, Antonios
Menacher, Martina
Akgün, Katja
Kleinschnitz, Christoph
Ruck, Tobias
Ziemssen, Tjalf
Pul, Refik
Meuth, Sven G. http://orcid.org/0000-0003-2571-3501
Article History
Received: 27 May 2022
Accepted: 10 October 2022
First Online: 7 November 2022
Declarations
:
: Before trial initiation, an ethics committee was consulted and approved the study (University of Duesseldorf, No. 5794R). The study was conducted in accordance with the Declaration of Helsinki.
: Participants provided written informed consent prior to inclusion.
: LRN no conflict of interest. MP received research funding from Novartis and honoraria for lecturing from ArgenX and Merck. His research is founded by the German Multiple Sclerosis Society North Rhine-Westphalia (DMSG) and the program “Innovative Medizinische Forschung “(IMF) of the Medical Faculty of the University of Muenster. AW no conflict of interest. LR received travel reimbursements from Merck Serono and Sanofi-Aventis. SHO no conflict of interest. CN no conflict of interest. TK no conflict of interest. MK received honoraria for lecturing and travel expenses for attending meetings from Merck Serono, Novartis, Hexal and Biogen. MG received honoraria and travel reimbursements for attending meetings from Biogen, Celgene, Merck Serono, Novartis, Roche, Sanofi Genzyme, TEVA. His research is funded by German Ministry for Education and Research (BMBF), Merck Serono and Novartis. SG no conflict of interest. FL no conflict of interest. SE no conflict of interest. GN has received personal compensation from Novartis for serving as a Consultant and on a Speakers Bureau. EB received personal compensation from Bayer vital, Novartis, Genzyme Sanofi, Janssen, Merck, Roche and TEVA. HR received honoraria for lecturing and consulting from von Novartis, MerckSerono, Roche, Bristol-Myers Squib, Biogen and Teva. AF received honoraria for lecturing and consulting from: Bayer, BIAL, Biogen, Bristol-Myers Squibb (BMS), Janssen-Cilag, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Teva. PK received honoraria for lecturing and consulting from Biogen, Bristol-Myers Squibb (BMS), Janssen-Cilag, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Teva, Bayer. HL received honoraria for lecturing and consulting from: Novartis, Roche, Shire, Takeda, Teva, Bayer. ZB received personal compensation from Novartis, Merck Serono, Roche, Bayer, Sanofi Genzyme, Teva, Biogen and Bristol-Myers Squibb. ME received honoraria for lecturing and consulting from TEVA, Biogen, Merck, Roche, Sanofi Aventis, Lilly and Celgene/BMS. AB received personal compensation from Merck Serono, Biogen, Novartis, TEVA, Roche, Sanofi/Genzyme, Celgene/Bristol Myers Squibb and Janssen; he received grants for congress travel and participation from Biogen, TEVA, Novartis, Sanofi/Genzyme, Merck Serono and Celgene. MM no conflict of interest related to the manuscript. KA reports consulting or serving on speaker bureaus for Roche, Sanofi, Alexion, Teva, BMS, Merck and Celgene. CK received remuneration for lectures and advisory boards from Alexion, Almirall, Bayer, Biogen, Boehringer Ingelheim, Bristol Myers-Squibb, Celgene, CSL Behring, Daiichi Sankyo, GE Healthcare, MedDay Pharmaceuticals, Merck Serono, Mylan/Viatris, Novartis, Pfizer, Roche, Sanofi-Genzyme, Stada, Teva, Biontech, Janssen-Cilag, Horizon Therapeutics GmbH, Medscape LLC, Baumgart Consultants GmbH. TR reports grants from German Ministry of Education, Science, Research and Technology, grants and personal fees from Sanofi-Aventis and Alexion; personal fees from Biogen Idec, Roche and Teva; personal fees and nonfinancial support from Merck Serono, outside the submitted work. TZ reports grants and study funding as well as speaking resp. consulting fees from Biogen, BMS, Hexal, Roche, Merck, TEVA, Novartis, Sanofi and Viatris. RP received honoraria for lectures and travel grants from Alexion, Bayer, Biogen, Celgene, MedDay, Merck, Mylan, Novartis, Roche, Sanofi Aventis, and TEVA. He received research grants from Novartis and Merck. SGM received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut für Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.